IBDEI0K7 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8911,1,4,0)
 ;;=4^R33.9
 ;;^UTILITY(U,$J,358.3,8911,2)
 ;;=^5019332
 ;;^UTILITY(U,$J,358.3,8912,0)
 ;;=D51.8^^69^606^2
 ;;^UTILITY(U,$J,358.3,8912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8912,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,8912,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,8912,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,8913,0)
 ;;=D52.9^^69^606^1
 ;;^UTILITY(U,$J,358.3,8913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8913,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,8913,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,8913,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,8914,0)
 ;;=I10.^^69^607^12
 ;;^UTILITY(U,$J,358.3,8914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8914,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,8914,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,8914,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,8915,0)
 ;;=I15.0^^69^607^13
 ;;^UTILITY(U,$J,358.3,8915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8915,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,8915,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,8915,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,8916,0)
 ;;=I13.11^^69^607^8
 ;;^UTILITY(U,$J,358.3,8916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8916,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,8916,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,8916,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,8917,0)
 ;;=I13.2^^69^607^7
 ;;^UTILITY(U,$J,358.3,8917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8917,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,8917,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,8917,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,8918,0)
 ;;=I70.1^^69^607^3
 ;;^UTILITY(U,$J,358.3,8918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8918,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,8918,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,8918,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,8919,0)
 ;;=I77.3^^69^607^2
 ;;^UTILITY(U,$J,358.3,8919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8919,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,8919,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,8919,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,8920,0)
 ;;=E26.02^^69^607^5
 ;;^UTILITY(U,$J,358.3,8920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8920,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,8920,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,8920,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,8921,0)
 ;;=I12.9^^69^607^14
 ;;^UTILITY(U,$J,358.3,8921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8921,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,8921,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,8921,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,8922,0)
 ;;=I12.0^^69^607^15
 ;;^UTILITY(U,$J,358.3,8922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8922,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,8922,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,8922,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,8923,0)
 ;;=I13.0^^69^607^6
 ;;^UTILITY(U,$J,358.3,8923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8923,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,8923,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,8923,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,8924,0)
 ;;=I13.10^^69^607^9
